: iStockAnalyst.com Symbols Feed

Closing: Slim Gain Enough To Land DJIA At New 2009 Closing High

Mon, 12 Oct 2009 20:25:00 GMT

Stock averages close narrowly mixed late in the session, having given up broad early gains. The DJIA finished up 0.2%. The S&P 500 edged up 0.4%. The tech-concentrated Nasdaq Composite ends just in the red, down less than 0.1%.[More...]

Stocks To Gain On Back Of Overseas Rally, Commodities Buzz

Wed, 10 Jun 2009 13:25:26 GMT

Futures continue to indicate solid opening stock gains. U.S. markets look to build on the commodities-inspired gains seen in Asia and Europe.[More...]

Texas Instruments, Ceradyne are big movers

Tue, 09 Jun 2009 22:12:00 GMT

NEW YORK - Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and Nasdaq Stock Market:
The chip maker hiked its profit and sales guidance for the quarter ending in June, signalling a rebound for the semiconductor sector.
The outdoor apparel company swung to a second-quarter profit, but a weak outlook and expensive new loan facilities worried analysts.

[More...]

BRIEF: MDRNA Gets $7.25 Million in Licensing Pact

Mon, 23 Mar 2009 21:51:00 GMT

Mar. 23--Bothell biotechnology company MDRNA said it inked a technology licensing deal with drug giant Novartis that provides an upfront payment of $7.25 million.
The two also are working on a broader agreement to collaborate on the local company's drug delivery technology.
Copyright (c) 2009, Seattle Times

[More...]

MDRNA, Inc. Receives NASDAQ Notification

Thu, 12 Nov 2009 20:47:00 GMT

MDRNA, Inc. (NASDAQ: MRNA) announced today that on November 6, 2009 it received a letter from The NASDAQ Stock Market, Inc. notifying the Company that, for ten consecutive business days, based on the Company's Market Value of Listed Securities (MVLS), it did not comply with the $50 million minimum MVLS for continued listing on The NASDAQ Global Market set forth in NASDAQ Marketplace Rule 5450(b)(3)(A).
MDRNA will continue to be listed on the NASDAQ Global Market during this period.
Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA to obtain additional funding; (ii) the ability of MDRNA to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA and/or a partner to develop and commercialize products that can compete favorably with those of competitors.

[More...]

MDRNA, Inc. Appoints James M. Karis to Its Board of Directors

Tue, 11 Aug 2009 13:10:00 GMT

BOTHELL, WA -- -- 08/11/09 -- MDRNA, Inc. announced today that James M. Karis has been appointed to the Company's Board of Directors. His appointment brings the number of MDRNA board members to six.[More...]

MDRNA, Inc. to Present at the 29th Canaccord Adams Global Growth Conference

Thu, 06 Aug 2009 17:11:00 GMT

BOTHELL, WA -- -- 08/06/09 -- MDRNA, Inc. announced today that it will present at the 29th annual Canaccord Adams Global Growth Conference on Wednesday, August 12, 2009, at 3:00 p.m. Eastern Time at the InterContinental Hotel in Boston, Massachusetts. J. Michael French, MDRNA's President and Chief Executive Officer, will present a corporate overview and business update.[More...]

BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update

Thu, 06 Aug 2009 10:48:00 GMT

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), The Leading Provider of Real Estate to the Life Science Industry(R), announced today that its board of directors and corporate officers will ring The Closing Bell(R) at the New York Stock Exchange on Thursday, August 6, 2009 at 4:00 p.m. Eastern Time to commemorate the fifth anniversary of the company's initial public offering.
BioMed's founders, Alan D. Gold, Chairman and Chief Executive Officer, and Gary A. Kreitzer, Executive Vice President, General Counsel and Director, will preside over the ringing of The Closing Bell(R).
"This is a great day for our team," said Mr. Gold.

[More...]

MDRNA, Inc. Reports Positive In Vivo Data Demonstrating That Its UsiRNAs Are Highly Potent Against Metabolic and Oncology Targets

Mon, 03 Aug 2009 11:56:00 GMT

BOTHELL, WA -- -- 08/03/09 -- MDRNA, Inc. announced today positive data on its proprietary UsiRNA technology, demonstrating that its UsiRNAs are highly potent against metabolic disease and cancer targets in rodent models. Further, the data establish that the knockdown of these targets is achieved via an RNAi-mediated process. Of particular importance is that the data demonstrate that strategic placement of UNA results in the ability to manipulate, either increasing or decreasing, strand-specific activity thus minimizing off-target activity and providing the ability to impart improved drug-like characteristics to the UsiRNAs. The data are being presented today by Michael V. Templin, Ph.D., Vice President, Discovery Research and Pharmaceutical Development of MDRNA, at the IBC Drug Discovery & Development Week, Oligonucleotide Therapeutics: From Concept to Implementation, in Boston, Massachusetts.[More...]

MDRNA, Inc. Announces Second Quarter 2009 Financial Results

Wed, 29 Jul 2009 19:56:00 GMT

BOTHELL, WA -- -- 07/29/09 -- MDRNA, Inc. today reported financial results for the three- and six-month periods ended June 30, 2009. Net loss for the second quarter of 2009 was approximately $7.5 million or $0.21 per share, compared to a net loss of approximately $14.3 million or $0.48 per share for the same period of 2008. The net loss for the six months ended June 30, 2009 was approximately $0.3 million or $0.01 per share, compared to approximately $30.8 million or $1.10 per share for the prior year same six-month period.[More...]

MDRNA Appoints New Chief Financial Officer

Tue, 14 Jul 2009 11:56:00 GMT

BOTHELL, WA -- -- 07/14/09 -- MDRNA, Inc. announced today the appointment of Peter S. Garcia as Chief Financial Officer and Secretary, reporting to the President and CEO. Mr. Garcia will lead and direct corporate financial and financing activities, investor and public relations efforts, as well as facilities and information technology operations for the Company.[More...]

MDRNA, Inc. Regains Full Compliance With All Marketplace Rules to Remain on the NASDAQ Global Market

Tue, 23 Jun 2009 11:56:00 GMT

BOTHELL, WA -- -- 06/23/09 -- MDRNA, Inc. announced today that on June 22, 2009, it received a letter from The NASDAQ Stock Market, LLC notifying the Company that it has regained full compliance with all requirements for remaining on The NASDAQ Global Market, specifically NASDAQ Marketplace Rule 5450 , which requires, among other things, a minimum market value of listed securities of $50.0 million ).[More...]

InvestorSoup.com's Updates for: Toll Brothers, e.Digital, SIRIUS, EMCORE, Eastman Kodak, MDRNA

Wed, 17 Jun 2009 15:05:00 GMT

Investment opinion and market research leader InvestorSoup.com announces the availability of free, detailed stock alerts on leading, active stocks in today's news. Each stock alert highlights recent news, trading activity, technical analysis and relevant market research you need to know.[More...]

MDRNA, Inc. Receives Full FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis

Tue, 09 Jun 2009 11:57:00 GMT

BOTHELL, WA -- -- 06/09/09 -- MDRNA, Inc. announced today that it has obtained full U.S. Food and Drug Administration approval of its Abbreviated New Drug Application for generic calcitonin-salmon nasal spray for the treatment of osteoporosis and that Par Pharmaceutical Companies, Inc. has launched the product.[More...]